Differentiating Molecular Risk Assessments for Prostate Cancer.

Reviews in urology Pub Date : 2018-01-01 DOI:10.3909/riu0787
Benjamin Press, Michael Schulster, Marc A Bjurlin
{"title":"Differentiating Molecular Risk Assessments for Prostate Cancer.","authors":"Benjamin Press,&nbsp;Michael Schulster,&nbsp;Marc A Bjurlin","doi":"10.3909/riu0787","DOIUrl":null,"url":null,"abstract":"<p><p>It is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of \"significant\" prostate cancer. Herein we discuss these tests and their clinical implications.</p>","PeriodicalId":21185,"journal":{"name":"Reviews in urology","volume":"20 1","pages":"12-18"},"PeriodicalIF":0.0000,"publicationDate":"2018-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6003298/pdf/RIU020001_012.pdf","citationCount":"8","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in urology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3909/riu0787","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 8

Abstract

It is critically important to the evolving goals of prostate biopsy to find clinically significant cancer with lethal potential and avoid detection of indolent disease. Better tests and markers are required for improved detection of clinically significant prostate cancer and avoidance of biopsies in men with indolent disease. Currently, there are myriad alternative prostate cancer risk-assessment tests available derived from serum and urine that are designed to improve the specificity for detection of "significant" prostate cancer. Herein we discuss these tests and their clinical implications.

Abstract Image

前列腺癌鉴别分子风险评估。
对于前列腺活检不断发展的目标来说,发现具有致命潜力的临床显著癌症和避免发现惰性疾病是至关重要的。需要更好的测试和标记来改进对临床显著前列腺癌的检测,并避免对患有惰性疾病的男性进行活组织检查。目前,有无数种从血清和尿液中提取的前列腺癌风险评估测试,旨在提高检测“重大”前列腺癌的特异性。在此,我们讨论这些测试及其临床意义。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信